CY1110535T1 - Μεταλλαξεις του γονιδιου της παρκινης, συνθεσεις, μεθοδοι και χρησεις - Google Patents

Μεταλλαξεις του γονιδιου της παρκινης, συνθεσεις, μεθοδοι και χρησεις

Info

Publication number
CY1110535T1
CY1110535T1 CY20091101178T CY091101178T CY1110535T1 CY 1110535 T1 CY1110535 T1 CY 1110535T1 CY 20091101178 T CY20091101178 T CY 20091101178T CY 091101178 T CY091101178 T CY 091101178T CY 1110535 T1 CY1110535 T1 CY 1110535T1
Authority
CY
Cyprus
Prior art keywords
parkin
gene
exons
deletion
amplifying
Prior art date
Application number
CY20091101178T
Other languages
English (en)
Inventor
Alexis Brice
Christophe Lucking
Nacer Eddine Abbas
Patrice Denefle
Sylvain Ricard
Sandrine Bouley
Original Assignee
Aventis Pharma S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9814524A external-priority patent/FR2786199B1/fr
Priority claimed from FR9910140A external-priority patent/FR2797272B1/fr
Application filed by Aventis Pharma S.A. filed Critical Aventis Pharma S.A.
Publication of CY1110535T1 publication Critical patent/CY1110535T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/104—Aminoacyltransferases (2.3.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/93—Ligases (6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y603/00—Ligases forming carbon-nitrogen bonds (6.3)
    • C12Y603/02—Acid—amino-acid ligases (peptide synthases)(6.3.2)
    • C12Y603/02019—Ubiquitin-protein ligase (6.3.2.19), i.e. ubiquitin-conjugating enzyme

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Η παρούσα εφεύρεση αφορά σε νουκλεϊκά οξέα τα οποία κωδικοποιούν τις μεταλλαγμένες, τις περικομμένες ή τις φέρουσες πολλαπλασιασμούς εξονίων μορφές της ανθρώπινης παρκίνης, και τις αντίστοιχες πρωτεΐνες και αντισώματα. Αφορά επίσης σε μεθόδους και κιτία για την ταυτοποίηση μεταλλάξεων του γονιδίου της παρκίνης, καθώς και στην μελέτη ενώσεων με θεραπευτικό σκοπό.
CY20091101178T 1998-11-19 2009-11-11 Μεταλλαξεις του γονιδιου της παρκινης, συνθεσεις, μεθοδοι και χρησεις CY1110535T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR9814524A FR2786199B1 (fr) 1998-11-19 1998-11-19 Mutations du gene de la parkine, compositions, methodes et utilisations
US12423999P 1999-03-12 1999-03-12
FR9910140A FR2797272B1 (fr) 1999-08-04 1999-08-04 Nouvelles mutations du gene de la parkine, compositions, methodes et utilisations
EP99956079A EP1131424B1 (fr) 1998-11-19 1999-11-18 Mutations du gene de la parkine, compositions, methodes et utilisations

Publications (1)

Publication Number Publication Date
CY1110535T1 true CY1110535T1 (el) 2015-04-29

Family

ID=27253486

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20091101178T CY1110535T1 (el) 1998-11-19 2009-11-11 Μεταλλαξεις του γονιδιου της παρκινης, συνθεσεις, μεθοδοι και χρησεις

Country Status (15)

Country Link
US (3) US8835618B2 (el)
EP (5) EP2305816A1 (el)
JP (1) JP5424519B2 (el)
AT (1) ATE440138T1 (el)
AU (1) AU778281B2 (el)
CA (1) CA2351567C (el)
CY (1) CY1110535T1 (el)
DE (1) DE69941300D1 (el)
DK (1) DK1131424T3 (el)
ES (1) ES2330281T3 (el)
IL (3) IL142755A0 (el)
NO (5) NO330896B1 (el)
NZ (1) NZ512313A (el)
PT (1) PT1131424E (el)
WO (1) WO2000031253A2 (el)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1081225A1 (en) * 1999-08-30 2001-03-07 Biofrontera Pharmaceuticals GmbH Transgenic animal model for neurodegenerative diseases
WO2001092576A1 (en) * 2000-05-26 2001-12-06 Duke University Methods of screening for parkinson's disease
FR2845245A1 (fr) * 2002-10-07 2004-04-09 Aventis Pharma Sa Modele animal de la maladie de parkinson
US7790390B2 (en) 2004-10-27 2010-09-07 Duke University Methods for identifying an individual at increased risk of developing coronary artery disease
US7807465B2 (en) 2004-10-27 2010-10-05 Duke University Methods for identifying an individual at increased risk of developing coronary artery disease
CN110295147A (zh) * 2019-07-22 2019-10-01 新乡医学院 一种食管癌细胞系中功能基因敲除后增殖表型的快速鉴定方法及其应用
WO2021237158A1 (en) * 2020-05-21 2021-11-25 Nysnobio Gt, Llc Gene therapy delivery of parkin mutants having increased activity to treat parkinson's disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69435058T2 (de) * 1993-10-05 2008-04-30 Asahi Glass Co., Ltd. Multicloning-vektor, expressionsvektor und herstellung von fremdproteinen unter verwendung des expressionsvektors
EP0873419B1 (en) 1995-06-06 2001-11-21 Beth Israel Deaconess Medical Center Method of and apparatus for diagnostic dna testing
ES2257029T3 (es) 1998-02-09 2006-07-16 Boehringer Ingelheim International Gmbh Dnas o genes que participan en la enfermedad de parkinson.
US7998667B1 (en) * 1998-11-19 2011-08-16 Aventis Pharma S.A. Mutations of the parkin gene, compositions, methods and uses

Also Published As

Publication number Publication date
US9540693B2 (en) 2017-01-10
IL142755A0 (en) 2002-03-10
EP2128257A2 (fr) 2009-12-02
CA2351567C (fr) 2016-01-12
DK1131424T3 (da) 2009-11-23
NO20110580L (no) 2001-07-18
NO333907B1 (no) 2013-10-14
US20170183736A1 (en) 2017-06-29
NO332174B1 (no) 2012-07-16
DE69941300D1 (de) 2009-10-01
AU1276900A (en) 2000-06-13
CA2351567A1 (fr) 2000-06-02
AU778281B2 (en) 2004-11-25
NO20110577L (no) 2001-07-18
NO330896B1 (no) 2011-08-08
NZ512313A (en) 2003-12-19
NO20110582L (no) 2001-07-18
EP2128257A3 (fr) 2010-03-03
US20150074836A1 (en) 2015-03-12
WO2000031253A2 (fr) 2000-06-02
EP2305816A1 (fr) 2011-04-06
IL142755A (en) 2009-08-03
ATE440138T1 (de) 2009-09-15
NO20110578L (no) 2001-07-18
PT1131424E (pt) 2009-10-23
EP1131424B1 (fr) 2009-08-19
NO333906B1 (no) 2013-10-14
EP1131424A2 (fr) 2001-09-12
IL187652A (en) 2010-02-17
WO2000031253A3 (fr) 2000-09-28
NO332173B1 (no) 2012-07-16
EP2345722A1 (fr) 2011-07-20
US8835618B2 (en) 2014-09-16
US20120064598A1 (en) 2012-03-15
JP5424519B2 (ja) 2014-02-26
ES2330281T3 (es) 2009-12-07
NO20012342L (no) 2001-07-18
JP2002536961A (ja) 2002-11-05
EP2311954A1 (fr) 2011-04-20
NO20012342D0 (no) 2001-05-11

Similar Documents

Publication Publication Date Title
CY1110535T1 (el) Μεταλλαξεις του γονιδιου της παρκινης, συνθεσεις, μεθοδοι και χρησεις
Manchenko Handbook of detection of enzymes on electrophoretic gels
GB2375539A (en) Human genome-derived single exon nucleic acid probes useful for analysis of gene expression in human adult liver
ATE310819T1 (de) Säugetieren apoptosis inhibitorprotein genfamilie,primers, probes und verfahren zur nachweis
Curchoe et al. Promoter-specific expression of the imprinted IGF2 gene in cattle (Bos taurus)
WO1999043808A8 (en) Human c-maf compositions and methods of use thereof
DE69808743T2 (de) Netrinrezeptoren
AU614489B2 (en) Compositions and methods for clones containing dna sequences associated with multidrug resistance in human cells
Cao et al. MMP‐1 promoter gene polymorphism and susceptibility to chronic periodontitis in a Chinese population
Owerbach et al. Inheritance of a parotid secretory protein in mice and its use in determining salivary amylase quantitative variants
Lee et al. Analysis of lung tumorigenesis in chimeric mice indicates the Pulmonary adenoma resistance 2 (Par2) locus to operate in the tumor-initiation stage in a cell-autonomous manner: detection of polymorphisms in the Polı gene as a candidate for Par2
Sasaki et al. Extensive morphological convergence and rapid radiation in the evolutionary history of the family Geoemydidae (Old World pond turtles) revealed by SINE insertion analysis
DE60023691D1 (de) T-bet zusammensetzungen und deren vervendungsmethoden
Van Zutphen Serum esterase genetics in rabbits. II. Genetic analysis of the prealbumin esterase system, including atropinesterase and cocainesterase polymorphism
ATE373095T1 (de) Mutierte muskelspezifische enhancer
CN101240325A (zh) 一种检测遗传基因修复能力的试剂盒
ATE386140T1 (de) Methoden und reagenzien zur in situ amplifizierung
WO2002086113A3 (en) Enzyme and snp marker for disease
EP1446485A4 (en) DIAGNOSIS PROCEDURE FOR CANCER MARKED BY IDENTIFICATION OF THE DELETION OF THE G-CSF EXONS 3
Silverton CRIME AND THE SCHIZOPHRENIA SPECTRUM: A STUDY OF TWO DANISH COHORTS.
Henry Differentiation of allozyme loci to distinguish between two species of Eisenia
Friedberg et al. Calculation and verification of the ages of retroprocessed pseudogenes
Ledford CRISPR hack transform s cells into data recorders
Basset et al. Identification of three Sorex species with microsatellite markers
JP2005507665A5 (el)